• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

作者信息

Zackova Daniela, Klamova Hana, Dusek Ladislav, Muzik Jan, Polakova Katerina Machova, Moravcova Jana, Jurcek Tomas, Dvorakova Dana, Racil Zdenek, Pospisil Zdenek, Oltova Alexandra, Michalova Kyra, Brezinova Jana, Razga Filip, Doubek Michael, Cetkovsky Petr, Trneny Marek, Mayer Jiri

机构信息

Department of Internal Medicine Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.

出版信息

Am J Hematol. 2011 Mar;86(3):318-21. doi: 10.1002/ajh.21942. Epub 2011 Feb 15.

DOI:10.1002/ajh.21942
PMID:21328429
Abstract
摘要

相似文献

1
Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?伊马替尼作为慢性期诊断的慢性髓性白血病患者的一线治疗：我们能否将真实生活数据与临床试验结果进行比较？
Am J Hematol. 2011 Mar;86(3):318-21. doi: 10.1002/ajh.21942. Epub 2011 Feb 15.
2
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.甲磺酸伊马替尼治疗可改善新诊断的慢性期费城染色体阳性慢性髓性白血病患者的生存率：与历史数据比较。
Cancer. 2003 Dec 15;98(12):2636-42. doi: 10.1002/cncr.11831.
3
Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.伊马替尼及其他——慢性粒细胞白血病新研究IV。新诊断慢性期慢性髓性白血病中伊马替尼与伊马替尼/α干扰素、伊马替尼/小剂量阿糖胞苷以及α干扰素治疗失败后伊马替尼的随机对照比较。
Ann Hematol. 2004 Apr;83(4):258-64. doi: 10.1007/s00277-003-0807-x. Epub 2003 Nov 29.
4
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.伊马替尼与干扰素和小剂量阿糖胞苷治疗新诊断慢性期慢性髓性白血病的比较
N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457.
5
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.伊马替尼与干扰素α加小剂量阿糖胞苷治疗新诊断慢性期慢性髓性白血病患者的生活质量：IRIS研究结果
J Clin Oncol. 2003 Jun 1;21(11):2138-46. doi: 10.1200/JCO.2003.12.154.
6
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.甲磺酸伊马替尼治疗对干扰素耐药或不耐受的慢性期慢性髓性白血病：150例患者的疗效及反应和无进展生存的预后因素
Haematologica. 2003 Oct;88(10):1117-22.
7
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.接受伊马替尼治疗超过5年的慢性期慢性髓性白血病患者，其BCR-ABL信使核糖核酸水平持续下降，并且按照严格的敏感性标准，所有一线治疗患者中约有一半的患者可稳定检测不到BCR-ABL。
Clin Cancer Res. 2007 Dec 1;13(23):7080-5. doi: 10.1158/1078-0432.CCR-07-0844.
8
[Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1660-2.
9
Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.甲磺酸伊马替尼可导致慢性髓性白血病慢性期晚期患者出现低磷血症，且这种效应与疗效相关。
Am J Hematol. 2007 May;82(5):394-5. doi: 10.1002/ajh.20778.
10
Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.甲磺酸伊马替尼治疗慢性期慢性髓性白血病的持续优异长期疗效和细胞遗传学反应：来自发展中国家的报告。
Jpn J Clin Oncol. 2010 Jun;40(6):549-55. doi: 10.1093/jjco/hyq012. Epub 2010 Feb 26.

引用本文的文献

1
Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data.转移性肾细胞癌患者的实际治疗模式和无进展生存情况：回顾性分析横断面数据。
BMC Cancer. 2018 Feb 21;18(1):214. doi: 10.1186/s12885-018-4117-z.
2
Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.口服治疗新时代慢性髓性白血病患者生存的决定因素：来自英国基于人群的患者队列的研究结果
BMJ Open. 2014 Jan 15;4(1):e004266. doi: 10.1136/bmjopen-2013-004266.
3
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
接受或未接受临床试验治疗的慢性髓性白血病患者的相似结局。
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):693-9. doi: 10.1016/j.clml.2013.05.011. Epub 2013 Sep 20.
4
Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.评估 458 例 CP-CML 患者在常规临床实践中的 5 年伊马替尼治疗效果及不同 BCR-ABL 截断值的预后影响。
Cancer Med. 2013 Apr;2(2):216-25. doi: 10.1002/cam4.59. Epub 2013 Feb 21.
5
How I treat newly diagnosed chronic phase CML.我如何治疗新诊断的慢性期 CML。
Blood. 2012 Aug 16;120(7):1390-7. doi: 10.1182/blood-2012-03-378919. Epub 2012 May 21.
6
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.现代药物治疗时代慢性髓性白血病患者无白血病生存和当前无白血病生存的当前累积发生率估计。
BMC Med Res Methodol. 2011 Oct 11;11:140. doi: 10.1186/1471-2288-11-140.